It has been shown that high-risk, MYCN-amplified neuroblastomas are more susceptible to OxPhos inhibition (41, 42), which fits with the increased growth suppression in BE(2)C (MYCN-amplified) tumors compared to the SK-N-AS (MYCN nonamplified) tumors in this study. This evidence concerns the gene MYCN and neuroblastoma.